Drug use and antiretroviral adherence in methadone maintenance patients;Consumo de drogas y adherencia a la terapia antirretroviral de pacientes en programa de mantenimiento con metadona

Adicciones

Volumn 17, Issue 3, 2005, Pages 203-214

  Ladero Martín, Lucía ^a   Orejudo Hernández, Santos ^a   Carrobles Isabel, José Antonio ^b   Malo Aznar, Carmen ^c  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c Servicio de Educación de Huesca   (Spain)

Author keywords

Adherence; Drug addicts; Drug use; HAART; Methadone maintenance programme

Indexed keywords

ANTIRETROVIRUS AGENT; COCAINE; DIAMORPHINE; METHADONE; TRANQUILIZER;

ADULT; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DRUG ABUSE; FEMALE; HEROIN DEPENDENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; PATIENT COMPLIANCE; VIRUS LOAD;

EID: 27644437935     PISSN: 02144840     EISSN: None     Source Type: Journal    
DOI: 10.20882/adicciones.369     Document Type: Article

References (30)

1. Mocroft A, Johnson M, Phillips AN. Factors affecting survival in patients with the acquired immunodeficiency syndrome. AIDS 1996; 10: 1057-1065.
2. Gulick R, Mellors J, Harlir D, Eron J, Gonzalez C, Mc Manon D et al. Potent and sustained antiretroviral activity on indinavir, in combination with zidavudine and lamivudine. III Conference on Retrovirus and opportunistic infections. Washington, 1996.
3. Mathez D, Truchis P, Gorin I, Katlama C, Pialoux G, Saimot AG, et al. Ritonavir, AZT, DDC as a triple combination in AIDS patients. III Conference on Retrovirus and opportunistic infections. Washington, 1996.
4. Hammer SM, Yeny P. Antiretroviral therapy: Where are we? AIDS 1998; 12: 181-188.
5. Lange JM. Changing therapy in HIV. AIDS 1996; 10 Suppl 1: 27-30.
6. Haynes RB, Sackett DL, Taylor DW. Compliance in health care. Baltimore: The Johns Hopkins University Press; 1979.
7. Ballester R, Reinoso I, García S, Campos A. Adherencia al tratamiento en la infección por VIH. Análisis y modificación de conducta 2000; 26: 689-716.
8. Haynes RB. Strategies to improve compliance with referral appointments and prescribed medical regimens. En RB Haynes, DL Sackett, DW, Taylor (Eds) Compliance in heath care. Baltimore: The Johns Hopkins University Press; 1979. p 121-143.
9. DiMatteo MR, Linn LS, Chang BL, Cope DW. Affect and neutrality in physician behavior: A study of patients, values and satisfaction. Journal of Behavioral Medicine 1985; 8: 397-409.
10. Rodríguez-Marín, J. Psicología social de la salud. Madrid: Síntesis; 1995.
11. Wood E, Montaner JSG, Braitstein P, Yip B, Schecter MT, O'Shaughnessy MVO, et al. Elevated rates of antirretroviral treatment discontinuation among HIV-infected injection drug users: implications for drug policy and public health. International Journal of Drug Policy 2004; 15: 133-138.
12. Gordillo V, del Amo J, Soriano V, González-Lahoz J. Sociodemographic and psychological variables influencing adherence to antirretroviral therapy. AIDS 1999; 13: 1763-1769.
13. Riera M, De La Fuente L, Castanyer B, Puigventós F, Villalonga C, Ribas MA, et al. Adherencia a los fármacos antirretrovirales medida por la concentración de fármacos y el recuento de comprimidos. Variables relacionadas con una mala adherencia. Med Clin 2002; 119: 286-92.
14. 4 cell counts from 200 to 500 per cubic milimeter. New England Journal of Medicine 1996; 335: 1081-1090.
15. Ioannidis J, Bassett R, Hughes M, Volberding P, Sacks H, Lau J. Predictors and impact of patients lost to follow-up in a long-term randomized trial of immediate versus deferred antiretroviral treatment. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 22-30.
16. Moatti JR Carrieri M, Spire B, Gastaut J, Cassuto J, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS 2000; 14: 151-155.
17. Haubrich R, Little S, Currier J, Forthal D, Kemper C, Beall G, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999; 13: 1099-1107.
18. Witteveen E, Van Ameijden E. Drug users and HIV-Combination therapy (HAART): Factors which impede or facilitate adherence. Substance use & misuse 2002; 37: 1905-1925.
19. Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with zidovudine treatment. Archives of Internal Medicine 1994; 154: 1121-1127.
20. Ley P, Spelman MS. Communicating with the patient. London: Staple press; 1967.
21. Pedreira Andrade JD. 1999. Adherencia al tratamiento antiretroví rico del paciente infectado por VIH. Publication of SEISIDA 1999; 10: 167-168.
22. Metha S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS 1997; 11: 1665-1670.
23. Remor E. Valoración de la adhesión al tratamiento antirretroviral en pacientes HIV positivos. Psicothema 2002; 14: 262-267
24. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30 Supl 2: 171-176.
25. Knobel H, Codina C, Miró JM, Carmona A, García B, Antela A, et al. Recomendaciones GESIDA/SEFH/PNS para mejorar la adherencia al tratamiento antirretroviral. Enfermedades Infecciosas y Microbiología Clínica 2000; 18: 27-39.
26. Malow R, McPherson S, Klimas N, Antoni M, Schneiderman N, Penedo F, et al. Adherence to Complex Combination Antiretroviral Therapies by HIV-Positive Drug Abusers. Psychiatric Services 1998; 49: 1021-1022.
27. Fernández JJ, González MR Sáiz PA, Gutierrez E, Bobes J. Calidad de vida y severidad de la adicción en heroinómanos en tratamiento prolongado con metadona. Adicciones 1999; 11: 43-52.
28. Serrano M, Arrizabalaga I. Programa de mantenimiento con metadona. Una intervención multidisciplinar y comunitaria: un estudio de calidad de vida. En V Encuentro Nacional sobre drogodependencias y su enfoque comunitario. Cádiz 1998, p.135-142.
29. Broadhead RS, Heckathorn DD, Altice FL, Van Hulst Y, Carbone M, Friedland GH, et al. Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study. Social Science and Medicine 2002; 55: 235-246.
30. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canadá 2000 [abstract 800].